Arcturus Therapeutics Holdings, Inc. (ARCT)
13.03
-0.18
(-1.36%)
USD |
NASDAQ |
Oct 02, 16:00
13.02
-0.02
(-0.12%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (TTM) : 79.32M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 79.32M |
| March 31, 2026 | 87.94M |
| December 31, 2025 | 95.30M |
| September 30, 2025 | 101.81M |
| June 30, 2025 | 109.54M |
| March 31, 2025 | 120.13M |
| December 31, 2024 | 124.69M |
| September 30, 2024 | 123.10M |
| June 30, 2024 | 122.19M |
| March 31, 2024 | 118.82M |
| December 31, 2023 | 114.92M |
| September 30, 2023 | 112.59M |
| June 30, 2023 | 123.59M |
| March 31, 2023 | 127.50M |
| December 31, 2022 | 142.05M |
| September 30, 2022 | 149.50M |
| June 30, 2022 | 156.11M |
| March 31, 2022 | 164.00M |
| December 31, 2021 | 168.16M |
| September 30, 2021 | 161.31M |
| June 30, 2021 | 138.91M |
| March 31, 2021 | 106.78M |
| December 31, 2020 | 69.55M |
| September 30, 2020 | 56.45M |
| June 30, 2020 | 42.11M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.73M |
| December 31, 2019 | 33.64M |
| September 30, 2019 | 26.49M |
| June 30, 2019 | 23.41M |
| March 31, 2019 | 20.36M |
| December 31, 2018 | 16.98M |
| September 30, 2018 | 23.49M |
| June 30, 2018 | 20.58M |
| March 31, 2018 | 17.80M |
| December 31, 2017 | 15.92M |
| September 30, 2017 | 9.009M |
| June 30, 2017 | 14.35M |
| March 31, 2017 | 17.09M |
| December 31, 2016 | 18.39M |
| September 30, 2016 | 17.28M |
| June 30, 2016 | 13.73M |
| March 31, 2016 | 13.23M |
| December 31, 2015 | 13.46M |
| September 30, 2015 | 15.03M |
| June 30, 2015 | 20.94M |
| March 31, 2015 | 23.17M |
| December 31, 2014 | 25.10M |
| September 30, 2014 | 24.80M |
| June 30, 2014 | 18.11M |
| March 31, 2014 | 12.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Exelixis, Inc. | 824.32M |
| Ionis Pharmaceuticals, Inc. | 923.08M |
| United Therapeutics Corp. | 551.50M |
| PTC Therapeutics, Inc. | 433.31M |